Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles

被引:136
作者
Dufes, C
Muller, JM
Couet, W
Olivier, JC
Uchegbu, IF
Schätzlein, AG
机构
[1] Univ Glasgow, Beatson Labs, Canc Res UK Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland
[2] Fac Sci Poitiers, Lab Biol Interact Cellulaires, CNRS, UMR 6558, Poitiers, France
[3] Fac Med & Pharm, Pharm Galen & Biopharm Lab, Poitiers, France
[4] Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Pharmaceut Sci, Glasgow, Lanark, Scotland
关键词
doxorubicin; glucose niosomes; glycol chitosan; polymeric vesicles; transferrin;
D O I
10.1023/B:PHAM.0000012156.65125.01
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Purpose. The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Methods. Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Results. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. Conclusions. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 31 条
[1]
Anthoney DA, 1996, CANCER RES, V56, P1374
[2]
TRANSFERRIN RECEPTORS ASSOCIATE WITH DRUG-RESISTANCE IN CANCER-CELLS [J].
BARABAS, K ;
FAULK, WP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 197 (02) :702-708
[3]
Cantuaria G, 2001, CANCER-AM CANCER SOC, V92, P1144, DOI 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO
[4]
2-T
[5]
Expression and localization of GLUT1 and GLUT12 in prostate carcinoma [J].
Chandler, JD ;
Williams, ED ;
Slavin, JL ;
Best, JD ;
Rogers, S .
CANCER, 2003, 97 (08) :2035-2042
[6]
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood [J].
Chang, YS ;
di Tomaso, E ;
McDonald, DM ;
Jones, R ;
Jain, RK ;
Munn, LL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (26) :14608-14613
[7]
Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting [J].
Dufes, C ;
Schätzlein, AG ;
Tetley, L ;
Gray, AI ;
Watson, DG ;
Olivier, JC ;
Couet, W ;
Uchegbu, IF .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1250-1258
[8]
The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[9]
IN-VITRO CULTIVATION OF HUMAN TUMORS - ESTABLISHMENT OF CELL LINES DERIVED FROM A SERIES OF SOLID TUMORS [J].
GIARD, DJ ;
AARONSON, SA ;
TODARO, GJ ;
ARNSTEIN, P ;
KERSEY, JH ;
DOSIK, H ;
PARKS, WP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1973, 51 (05) :1417-1423
[10]
GODING J, 1999, CD71 NCBI PROTEINS W